WebSep 30, 2024 · IN10018 will be assessed firstly as monotherapy(Part 1), then in combination with cobimetinib (Part 2) and in combination with cobimetinib and … WebApr 13, 2024 · IN10018 is a potent and highly selective adenosine triphosphate competitive FAK inhibitor, and InxMed has its exclusive global development and commercial operation rights.
A phase Ib study of IN10018 in combination with pegylated …
WebMar 17, 2024 · Formerly known as BI853520, IN10018 is a potent and selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor. The drug is currently … WebBusiness Hours. 725 Canton Street, Norwood, MA 02062 - 781.620.8000 Monday - Friday: 8:00AM to 8:00PM ET siadh and lung cancer pathophysiology
InxMed doses first patient in cancer trial of IN10018
WebFeb 2, 2024 · FAK is encoded by the protein tyrosine kinase 2 (PTK2) gene located on chromosomal region 8q24.3. The structure of FAK is composed of an amino-terminal band 4.1–ezrin–radixin–moesin (FERM) domain, followed by a kinase domain, and a carboxy-terminal focal adhesion targeting (FAT) domain. WebMay 9, 2024 · IN10018 is a potent and highly selective adenosine triphosphate competitive FAK inhibitor, and InxMed has its exclusive global development and commercial operation rights. InxMed Nanjing Translational Medicine Center has conducted extensive original exploratory research on IN10018 and FAK targets and has published research results in … WebIN10018 is a highly potent and selective inhibitor of the focal adhesion kinase (FAK). Anti-tumor activities of IN10018 have been demonstrated in multiple animal models for human cancers. More than 250 patients have been dosed and IN10018 has showed its safety and promising efficacy signal in platinum ovarian cancer and NRAS melanoma. siadh and small cell lung cancer